1. Flaherty KR et al. N Engl J Med 2019;381:1718-1727.
2. Zamora-Legoff JA et al. Arthritis Rheumatol 2017;69:542-549.
3. Salisbury ML et al. Chest 2019;155:699-711.
4. Richeldi L et al. N Engl J Med 2014;370:2071-2082.

The INBUILD trial was funded by Boehringer Ingelheim. Editorial and formatting assistance, supported financially by Boehringer Ingelheim, was provided by Elizabeth Ng and Wendy Morris of FleishmanHillard Fishburn, London, UK during preparation of this poster. The authors were fully responsible for all content and editorial decisions, were involved at all stages of poster development and have approved the final version. Boehringer Ingelheim was given the opportunity to review the poster for medical and scientific accuracy as well as intellectual property considerations. The authors received no direct compensation related to the development of this poster. Kevin Brown reports grants from NHLBI; personal fees from Biogen, Blade Therapeutics, Galapagos, Galecto Biotech, Huitai Biomedicine, Lifemax, Lilly, MedImmune, monARC Bionetworks, Pliant Therapeutics, ProMetic, Third Pole Therapeutics, Theravance, Three Lakes Partners, and Veracyte; personal fees and non-financial support from Boehringer Ingelheim; and other support from Genoa and the Open Source Imaging Consortium (OSIC). Athol Wells reports personal fees from Blade Therapeutics, Boehringer Ingelheim, and InterMune/Roche.